15th November 2010

Mirada Medical to Showcase Innovative Oncology Imaging Software Portfolio at RSNA Annual Meeting

Mirada Medical Limited, the fast growing international company focused on advanced oncology imaging, announced today that it will be showcasing and launching new oncology imaging software designed to significantly improve productivity and communication between clinical specialists at the 2010 RSNA (Radiological Society of North America) trade show in Chicago, Illinois from November 28 - December 3, 2010. At the conference, Mirada will launch its novel solution for presenting image based patient case information at specialist meetings such as tumor boards, multi-disciplinary team (MDT) meetings and radiology rounds. Users of Mirada’s technology will be able to greatly reduce the time spent preparing multiple patient cases for presentation to the meeting, and will also benefit during the meeting from having instant access to the advanced visualisation and quantification features normally only available to the diagnostic reader. Mirada will also be demonstrating the unique oncology fusion workflows of its XD3 image analysis software, including new CT, MR, PET/CT and MR/PET analysis tools designed to enhance speed and accuracy across the complete spectrum of imaging tasks, from diagnosis and staging through to treatment response assessment and follow-up. The new tools coupled with Mirada’s industry leading deformable registration technology and built-in support for standard and user-defined response assessment protocols such as RECIST, WHO and PERCIST give the user exceptional power to review, compare and quantify a patient’s complete set of current and previous imaging studies. Mirada’s team will be available to show how the referring physician can now have access to rich web-based fusion viewing capabilities, allowing them to view PET/CT, MR-PET and even CT-MR-PET fused images, reports and findings that the reading radiologist or nuclear medicine clinician has sent. Mirada’s technologies are developed by world renowned scientists and dedicated engineers and the Company is focused on providing users with oncology imaging solutions to enhance their workflow whilst optimizing the most accurate and consistent reporting and quantitative knowledge share in the multi-modal diagnosis and treatment of cancer. Hugh Bettesworth, CEO of Mirada Medical, said: “We look forward to launching the final piece of our innovative suite of oncology imaging applications which together will offer not only the most advanced workflows in quantified diagnostic analysis of multi-modal images, but also significantly improve productivity and communication of findings when delivering these findings to the referring physician or presenting at specialist meetings such as tumor board. Mirada remains committed to the delivery of high quality healthcare solutions to its global customer base through the use of leading technologies.” Mirada Medical will showcase its latest and industry leading developments at Booth 7520, Hall B, North Building of McCormick Place.